Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141492
Status:
COMPLETED
Last Update Posted:
2015-01-21
First Post:
2005-08-30
Brief Title:
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
A Double Blind Randomized Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Androgel as an Adjunct to Hypoglycemic Therapy in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to investigate how well Androgel when tested against placebo gel helps to control blood sugar levels in males with type 2 diabetes who have low testosterone the main male hormone blood levels and are taking oral diabetic medicines alone or in combination with insulin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None